Author:
Landewé Robert B. M.,Connell Carol A.,Bradley John D.,Wilkinson Bethanie,Gruben David,Strengholt Sander,van der Heijde Désirée
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Rahman MU, Buchanan J, Doyle MK, Hsia EC, Gathany T, Parasuraman S, et al. Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. Ann Rheum Dis. 2011;70:1631–40.
2. American College of Rheumatology Rheumatoid Arthritis Clinical Trials Task Force Imaging Group and Outcome Measures in Rheumatology Magnetic Resonance Imaging Inflammatory Arthritis Working Group. Review: the utility of magnetic resonance imaging for assessing structural damage in randomized controlled trials in rheumatoid arthritis. Arthritis Rheum. 2013;65:2513–23.
3. Landewe R, Strand V, van der Heijde D. From inhibition of radiographic progression to maintaining structural integrity: a methodological framework for radiographic progression in rheumatoid arthritis and psoriatic arthritis clinical trials. Ann Rheum Dis. 2013;72:1113–7.
4. European Medicines Agency, CPMP. Points to consider on clinical investigation of medicinal products other than NSAIDs for treatment of rheumatoid arthritis. 2003. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003439.pdf . Accessed 1 Mar 2016.
5. American College of Rheumatology Rheumatoid Arthritis Clinical Trial Investigators Ad Hoc Task Force. American College of Rheumatology Clinical Trial Priorities and Design Conference, July 22–23, 2010. Arthritis Rheum. 2011;63:2151–6.
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献